Articles, Case Studies and Resources | Acumetis

What Is the EU’s pharmaceutical legislation agreement telling the industry?

Overview of the EU pharmaceutical legislation agreement and its implications for the industry, from market exclusivity to regulatory reform.

Strategic competitor analysis for gene therapy markets

Explore how gene therapy competitor analysis supports market entry strategy, competitive intelligence, market access planning, and long-term commercialization success.

Maximizing market potential with target patient population analysis

Explore how our team curated a target patient population analysis supporting pediatric and adult commercialization strategy, market assessment, and long-term growth planning.

The “direct” continuum: Decoding direct-to-patient and direct-to-employer for commercial success

Explore how DTP and DTE models are reshaping commercialization, improving patient access, affordability, engagement, and market strategy.

How strategic market access insights strengthen coverage and accelerate access

Explore how the Acumetis Advisor Network delivers real-world perspectives from payers, PBMs, IDNs, and global access leaders to support stronger market access strategy and decision making.

Strategic launch in a rare hematologic disease

Explore how Acumetis supported launch readiness for a novel rare hematologic disease therapy through scientific positioning, stakeholder engagement, KOL insights, and cross-functional Medical Affairs strategy.

Direct-to-patient access: Five questions pharma must answer

Direct-to-patient models are reshaping commercialization strategy. Explore key considerations around patient access, operational readiness, scalability, and DTP strategy in this Pharmaphorum interview with Acumetis.

Meet Acumetis at WODC US!

Meet Acumetis at WODC US 2026 in Boston. Connect with our GVA team and explore the evolving challenges of pricing, reimbursement, and patient access for orphan and rare disease therapies.

Optimizing Clinical Endpoints for Phase III Design

A Medical Affairs case study demonstrating how evidence review and stakeholder insight were used to refine clinically meaningful endpoints and support Phase III trial design and regulatory dialogue.